Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma.

Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma. Abstract Text:

Maurizio Martini,Stefan Hohaus,Giovanna Petrucci,Tonia Cenci,Francesco Pierconti,Giuseppina Massini,Luciana Teofili,Giuseppe Leone,Luigi M Larocca,

An important pathogenetic mechanism in Hodgkin lymphoma (HL) is the interaction between the neoplastic and reactive cells mediated by a complex network of cytokines with activation of cytokine signal transduction (STAT) pathways. We studied the prognostic impact of the phosphorylation status of STAT5 in HL.By using immunohistochemical analysis, we found phosphorylated STAT5 (pSTAT5) in 35 (38%) of 93 lymph node biopsy specimens of patients with HL. The detection of pSTAT5 in Hodgkin and Reed-Sternberg (HRS) cells in classical HL (cHL) was not associated with any clinical and biologic features evaluated, including Epstein-Barr virus status. The primary end point for analysis of clinical outcome was freedom from treatment failure (FFTF). At a median follow-up of 5 years, pSTAT5+ patients with cHL had a better FFTF than pSTAT5-patients (77% vs 56%; P = .03), which translated into a reduced risk for failure for pSTAT5+ patients with a hazard ratio of 0.2 (95% confidence interval, 0.06-0.73; P = .015).Our data suggest that the phosphorylation status of STAT5 of HRS cells in cHL could be a prognostic marker in HL.

Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma. Publishing Authors By Initials

M Martini,S Hohaus,G Petrucci,T Cenci,F Pierconti,G Massini,L Teofili,G Leone,LM Larocca,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: American journal of clinical pathology

VOLUME: 129

Page Numbers: 472-7

Journal Abbreviation: Am. J. Clin. Pathol.

ISSN: 0002-9173

DAY: 20

MONTH: Mar

YEAR: 2008

Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370470

Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma.

AFFILIATION: The Departments of Pathology, Catholic University of Rome, Rome, Italy.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Am J Clin Pathol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma Related Publications

• A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis.
• Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas.
• Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?
• Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases.
• Hydrogen peroxide-related colitis (previously known as "pseudolipomatosis"): a series of cases occurring in an epidemic pattern.
• Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma.
• Reduced vascular tetrahydrobiopterin (BH4) and endothelial function with ageing: is it time for a chronic BH4 supplementation trial in middle-aged and older adults?
• Reply to souza et Al.
• The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia.